Sharmilan Thanendrarajan
Concepts (239)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Multiple Myeloma | 60 | 2025 | 2998 | 4.150 |
Why?
| Antibodies, Bispecific | 6 | 2025 | 88 | 1.190 |
Why?
| Hematopoietic Stem Cell Transplantation | 9 | 2024 | 578 | 1.100 |
Why?
| Leukemia, Plasma Cell | 2 | 2020 | 32 | 0.860 |
Why?
| Immunotherapy, Adoptive | 5 | 2024 | 163 | 0.720 |
Why?
| Bone Marrow | 10 | 2022 | 363 | 0.690 |
Why?
| B-Cell Maturation Antigen | 7 | 2025 | 99 | 0.690 |
Why?
| Neoplasms, Plasma Cell | 3 | 2024 | 36 | 0.640 |
Why?
| Humans | 69 | 2025 | 50503 | 0.600 |
Why?
| Plasma Cells | 6 | 2023 | 221 | 0.590 |
Why?
| Chromosome Deletion | 2 | 2023 | 134 | 0.580 |
Why?
| Transplantation, Autologous | 10 | 2024 | 481 | 0.560 |
Why?
| Chromosomes, Human, Pair 17 | 1 | 2017 | 34 | 0.560 |
Why?
| Gene Expression Profiling | 10 | 2023 | 1025 | 0.540 |
Why?
| Tumor Suppressor Protein p53 | 2 | 2017 | 213 | 0.520 |
Why?
| Clinical Trials as Topic | 4 | 2022 | 486 | 0.520 |
Why?
| Gene Expression Regulation, Neoplastic | 6 | 2021 | 833 | 0.510 |
Why?
| Neoplasm, Residual | 6 | 2022 | 160 | 0.490 |
Why?
| Proteasome Inhibitors | 1 | 2016 | 104 | 0.480 |
Why?
| Immunologic Factors | 1 | 2016 | 111 | 0.480 |
Why?
| Monoclonal Gammopathy of Undetermined Significance | 4 | 2024 | 112 | 0.480 |
Why?
| Aged | 23 | 2025 | 9741 | 0.450 |
Why?
| Prognosis | 15 | 2024 | 1978 | 0.440 |
Why?
| Immunotherapy | 1 | 2016 | 235 | 0.440 |
Why?
| Stem Cell Transplantation | 5 | 2024 | 179 | 0.430 |
Why?
| Translocation, Genetic | 5 | 2021 | 240 | 0.430 |
Why?
| Mutation | 7 | 2022 | 1280 | 0.420 |
Why?
| Antibodies, Monoclonal | 2 | 2022 | 462 | 0.420 |
Why?
| Neoplasm Proteins | 4 | 2020 | 320 | 0.400 |
Why?
| Neutropenia | 2 | 2023 | 116 | 0.390 |
Why?
| Survival Analysis | 8 | 2024 | 661 | 0.380 |
Why?
| Neoplasms | 2 | 2012 | 1251 | 0.380 |
Why?
| Cytokine-Induced Killer Cells | 1 | 2011 | 2 | 0.380 |
Why?
| Lymphocytes | 1 | 2012 | 149 | 0.370 |
Why?
| Evolution, Molecular | 2 | 2021 | 95 | 0.350 |
Why?
| Cancer Vaccines | 1 | 2011 | 80 | 0.350 |
Why?
| Neoplasm Recurrence, Local | 7 | 2024 | 629 | 0.350 |
Why?
| Positron-Emission Tomography | 4 | 2022 | 292 | 0.340 |
Why?
| Diffusion Magnetic Resonance Imaging | 3 | 2019 | 125 | 0.330 |
Why?
| Cytokines | 1 | 2012 | 606 | 0.310 |
Why?
| Tumor Microenvironment | 3 | 2024 | 222 | 0.300 |
Why?
| Female | 27 | 2025 | 27081 | 0.300 |
Why?
| Middle Aged | 21 | 2025 | 12611 | 0.290 |
Why?
| Aged, 80 and over | 9 | 2025 | 3226 | 0.290 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2024 | 1000 | 0.290 |
Why?
| Hematologic Neoplasms | 2 | 2022 | 99 | 0.290 |
Why?
| Combined Modality Therapy | 4 | 2024 | 641 | 0.270 |
Why?
| Atrial Fibrillation | 2 | 2022 | 188 | 0.270 |
Why?
| Male | 25 | 2025 | 25907 | 0.250 |
Why?
| Adult | 17 | 2025 | 13577 | 0.240 |
Why?
| Fluorodeoxyglucose F18 | 4 | 2021 | 189 | 0.240 |
Why?
| Proto-Oncogene Proteins B-raf | 3 | 2020 | 80 | 0.230 |
Why?
| Immunoglobulins, Intravenous | 1 | 2025 | 65 | 0.230 |
Why?
| Polycomb Repressive Complex 2 | 2 | 2021 | 46 | 0.230 |
Why?
| Neoplasms, Second Primary | 1 | 2024 | 74 | 0.220 |
Why?
| Treatment Outcome | 8 | 2024 | 5283 | 0.220 |
Why?
| Chromosomes, Human, Pair 1 | 2 | 2023 | 92 | 0.210 |
Why?
| Disease Progression | 6 | 2021 | 829 | 0.200 |
Why?
| Risk Factors | 9 | 2024 | 3724 | 0.200 |
Why?
| Paraproteinemias | 1 | 2022 | 72 | 0.200 |
Why?
| Immunoconjugates | 1 | 2022 | 38 | 0.190 |
Why?
| Osteolysis | 1 | 2022 | 74 | 0.190 |
Why?
| Drug Approval | 1 | 2022 | 47 | 0.190 |
Why?
| Waldenstrom Macroglobulinemia | 1 | 2022 | 40 | 0.190 |
Why?
| Lymphoma, B-Cell | 1 | 2022 | 49 | 0.190 |
Why?
| Recurrence | 6 | 2024 | 659 | 0.190 |
Why?
| Epigenomics | 1 | 2021 | 68 | 0.190 |
Why?
| Patient Participation | 1 | 2022 | 70 | 0.190 |
Why?
| T-Lymphocytes | 4 | 2024 | 325 | 0.180 |
Why?
| Genes, Tumor Suppressor | 2 | 2021 | 73 | 0.180 |
Why?
| Cell Cycle | 1 | 2021 | 226 | 0.170 |
Why?
| Practice Guidelines as Topic | 1 | 2023 | 468 | 0.170 |
Why?
| Exosome Multienzyme Ribonuclease Complex | 1 | 2020 | 12 | 0.170 |
Why?
| Bone Resorption | 1 | 2022 | 302 | 0.170 |
Why?
| Bone Diseases | 1 | 2021 | 96 | 0.170 |
Why?
| Retrospective Studies | 8 | 2025 | 6263 | 0.170 |
Why?
| Gene Regulatory Networks | 1 | 2020 | 106 | 0.160 |
Why?
| Chromosomal Instability | 1 | 2019 | 16 | 0.160 |
Why?
| Hematopoiesis, Extramedullary | 1 | 2019 | 9 | 0.160 |
Why?
| Disease-Free Survival | 5 | 2019 | 444 | 0.160 |
Why?
| Antigens, CD | 1 | 2020 | 222 | 0.160 |
Why?
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2018 | 10 | 0.160 |
Why?
| Healthcare Disparities | 1 | 2022 | 281 | 0.160 |
Why?
| Spleen | 1 | 2019 | 169 | 0.150 |
Why?
| Spinal Fractures | 1 | 2018 | 38 | 0.150 |
Why?
| Phosphotransferases | 1 | 2018 | 16 | 0.150 |
Why?
| Antineoplastic Agents | 2 | 2024 | 1172 | 0.150 |
Why?
| Bacteremia | 1 | 2019 | 89 | 0.150 |
Why?
| Brain Neoplasms | 2 | 2011 | 291 | 0.150 |
Why?
| Adipocytes | 1 | 2018 | 126 | 0.140 |
Why?
| Gene Rearrangement | 1 | 2018 | 65 | 0.140 |
Why?
| Hexokinase | 1 | 2017 | 17 | 0.140 |
Why?
| Retinoblastoma Binding Proteins | 1 | 2017 | 11 | 0.140 |
Why?
| Calcification, Physiologic | 1 | 2017 | 40 | 0.140 |
Why?
| Epigenesis, Genetic | 1 | 2020 | 372 | 0.140 |
Why?
| Pelvis | 1 | 2017 | 66 | 0.140 |
Why?
| Cell Proliferation | 4 | 2023 | 985 | 0.130 |
Why?
| Lymphoma, Large B-Cell, Diffuse | 2 | 2022 | 90 | 0.130 |
Why?
| Survival Rate | 4 | 2020 | 909 | 0.130 |
Why?
| Immunoglobulin Light Chains | 1 | 2017 | 84 | 0.130 |
Why?
| Ubiquitin-Protein Ligases | 1 | 2017 | 95 | 0.130 |
Why?
| Clonal Evolution | 1 | 2016 | 56 | 0.130 |
Why?
| Flow Cytometry | 1 | 2018 | 474 | 0.130 |
Why?
| Gene Expression Regulation, Enzymologic | 1 | 2017 | 179 | 0.130 |
Why?
| Gene Expression | 1 | 2018 | 610 | 0.120 |
Why?
| Animals | 4 | 2024 | 13124 | 0.120 |
Why?
| Cystatin M | 2 | 2024 | 19 | 0.110 |
Why?
| Cross-Sectional Studies | 3 | 2023 | 1610 | 0.100 |
Why?
| Cardiovascular Diseases | 1 | 2017 | 461 | 0.100 |
Why?
| Follow-Up Studies | 3 | 2024 | 2242 | 0.090 |
Why?
| Lymphoma, Non-Hodgkin | 1 | 2011 | 55 | 0.090 |
Why?
| Astrocytoma | 1 | 2011 | 21 | 0.090 |
Why?
| Mutation Rate | 2 | 2021 | 35 | 0.090 |
Why?
| Disease Models, Animal | 1 | 2016 | 1436 | 0.090 |
Why?
| In Situ Hybridization, Fluorescence | 2 | 2023 | 231 | 0.090 |
Why?
| Glioma | 1 | 2011 | 77 | 0.090 |
Why?
| Alleles | 2 | 2021 | 256 | 0.080 |
Why?
| Genomics | 2 | 2023 | 279 | 0.080 |
Why?
| Remission Induction | 2 | 2021 | 208 | 0.080 |
Why?
| Tumor Burden | 2 | 2020 | 130 | 0.080 |
Why?
| Proto-Oncogene Proteins p21(ras) | 2 | 2021 | 67 | 0.080 |
Why?
| Histones | 2 | 2021 | 297 | 0.080 |
Why?
| Vaccination | 1 | 2011 | 280 | 0.080 |
Why?
| Transcription Factors | 2 | 2023 | 565 | 0.080 |
Why?
| DNA Copy Number Variations | 2 | 2021 | 109 | 0.080 |
Why?
| Radiopharmaceuticals | 2 | 2021 | 204 | 0.080 |
Why?
| Models, Biological | 1 | 2011 | 716 | 0.070 |
Why?
| Cell Differentiation | 2 | 2022 | 640 | 0.070 |
Why?
| Transcriptome | 2 | 2020 | 313 | 0.070 |
Why?
| Kaplan-Meier Estimate | 2 | 2019 | 464 | 0.070 |
Why?
| Imaging, Three-Dimensional | 2 | 2017 | 150 | 0.060 |
Why?
| Biopsy | 2 | 2018 | 588 | 0.060 |
Why?
| Arkansas | 2 | 2021 | 1985 | 0.060 |
Why?
| Killer Cells, Natural | 1 | 2024 | 106 | 0.060 |
Why?
| Ferritins | 1 | 2024 | 30 | 0.060 |
Why?
| Demography | 1 | 2024 | 94 | 0.060 |
Why?
| Myeloid Progenitor Cells | 1 | 2023 | 17 | 0.060 |
Why?
| X-Ray Microtomography | 1 | 2024 | 79 | 0.060 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2024 | 125 | 0.050 |
Why?
| Receptors, G-Protein-Coupled | 1 | 2024 | 49 | 0.050 |
Why?
| Antibodies | 1 | 2024 | 153 | 0.050 |
Why?
| Mice | 2 | 2024 | 5687 | 0.050 |
Why?
| Signal Transduction | 2 | 2021 | 1624 | 0.050 |
Why?
| TNF Receptor-Associated Factor 3 | 1 | 2022 | 13 | 0.050 |
Why?
| Patients | 1 | 2022 | 48 | 0.050 |
Why?
| Geography | 1 | 2022 | 60 | 0.050 |
Why?
| Myeloid Differentiation Factor 88 | 1 | 2022 | 32 | 0.050 |
Why?
| Patient Selection | 1 | 2023 | 259 | 0.050 |
Why?
| United States Food and Drug Administration | 1 | 2022 | 90 | 0.050 |
Why?
| Oncogenes | 1 | 2021 | 57 | 0.050 |
Why?
| Chromosome Aberrations | 1 | 2023 | 280 | 0.050 |
Why?
| Dexamethasone | 1 | 2024 | 432 | 0.050 |
Why?
| Phylogeny | 1 | 2022 | 236 | 0.050 |
Why?
| Bone Marrow Transplantation | 1 | 2022 | 136 | 0.050 |
Why?
| Syndecan-1 | 1 | 2021 | 75 | 0.050 |
Why?
| SOXC Transcription Factors | 1 | 2021 | 13 | 0.050 |
Why?
| RANK Ligand | 1 | 2022 | 187 | 0.050 |
Why?
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2022 | 81 | 0.050 |
Why?
| Transcriptional Activation | 1 | 2021 | 119 | 0.050 |
Why?
| Chromatin | 1 | 2021 | 137 | 0.050 |
Why?
| Clone Cells | 1 | 2021 | 70 | 0.050 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2022 | 226 | 0.040 |
Why?
| Pyrimidines | 1 | 2022 | 191 | 0.040 |
Why?
| Cyclin D2 | 1 | 2020 | 20 | 0.040 |
Why?
| Aneuploidy | 1 | 2020 | 18 | 0.040 |
Why?
| Proto-Oncogene Proteins c-maf | 1 | 2020 | 19 | 0.040 |
Why?
| Chromosomes, Human, Pair 4 | 1 | 2020 | 30 | 0.040 |
Why?
| Chromosomes, Human, Pair 11 | 1 | 2020 | 49 | 0.040 |
Why?
| Histone Code | 1 | 2020 | 30 | 0.040 |
Why?
| Gene Expression Regulation, Leukemic | 1 | 2020 | 29 | 0.040 |
Why?
| Cyclin D1 | 1 | 2020 | 52 | 0.040 |
Why?
| ras Proteins | 1 | 2020 | 64 | 0.040 |
Why?
| Genome, Human | 1 | 2021 | 109 | 0.040 |
Why?
| Protein Kinase Inhibitors | 1 | 2022 | 204 | 0.040 |
Why?
| Chromosomes, Human, Pair 14 | 1 | 2020 | 66 | 0.040 |
Why?
| DNA, Neoplasm | 1 | 2020 | 143 | 0.040 |
Why?
| Health Status Disparities | 1 | 2022 | 202 | 0.040 |
Why?
| Genetic Variation | 1 | 2020 | 207 | 0.040 |
Why?
| DNA Mutational Analysis | 1 | 2020 | 175 | 0.040 |
Why?
| Cell Line, Tumor | 1 | 2023 | 1398 | 0.040 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2020 | 169 | 0.040 |
Why?
| Osteoclasts | 1 | 2022 | 427 | 0.040 |
Why?
| Multivariate Analysis | 1 | 2021 | 583 | 0.040 |
Why?
| Gram-Positive Bacterial Infections | 1 | 2019 | 27 | 0.040 |
Why?
| Computational Biology | 1 | 2020 | 215 | 0.040 |
Why?
| Pseudomonas Infections | 1 | 2019 | 48 | 0.040 |
Why?
| Syndrome | 1 | 2019 | 240 | 0.040 |
Why?
| Fractures, Compression | 1 | 2018 | 17 | 0.040 |
Why?
| DNA-Binding Proteins | 1 | 2021 | 418 | 0.040 |
Why?
| Promoter Regions, Genetic | 1 | 2020 | 465 | 0.040 |
Why?
| Receptor Protein-Tyrosine Kinases | 1 | 2018 | 46 | 0.040 |
Why?
| Oncogene Proteins, Fusion | 1 | 2018 | 57 | 0.040 |
Why?
| 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2017 | 8 | 0.040 |
Why?
| Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2017 | 27 | 0.040 |
Why?
| Protein-Tyrosine Kinases | 1 | 2018 | 88 | 0.040 |
Why?
| Kidney Function Tests | 1 | 2017 | 51 | 0.040 |
Why?
| STAT3 Transcription Factor | 1 | 2017 | 77 | 0.040 |
Why?
| Retinoblastoma Protein | 1 | 2017 | 19 | 0.030 |
Why?
| False Positive Reactions | 1 | 2017 | 59 | 0.030 |
Why?
| Fibroblast Growth Factors | 1 | 2017 | 45 | 0.030 |
Why?
| Bone and Bones | 1 | 2021 | 478 | 0.030 |
Why?
| Glomerular Filtration Rate | 1 | 2017 | 119 | 0.030 |
Why?
| Mitogen-Activated Protein Kinases | 1 | 2017 | 155 | 0.030 |
Why?
| Amino Acid Sequence | 1 | 2018 | 574 | 0.030 |
Why?
| Alkaline Phosphatase | 1 | 2017 | 93 | 0.030 |
Why?
| Sequence Analysis, DNA | 1 | 2017 | 226 | 0.030 |
Why?
| Genes, ras | 1 | 2016 | 43 | 0.030 |
Why?
| Genes, p53 | 1 | 2016 | 49 | 0.030 |
Why?
| NF-kappa B | 1 | 2018 | 315 | 0.030 |
Why?
| Glycolysis | 1 | 2016 | 69 | 0.030 |
Why?
| DNA Methylation | 1 | 2020 | 550 | 0.030 |
Why?
| Models, Genetic | 1 | 2016 | 172 | 0.030 |
Why?
| Genomic Instability | 1 | 2016 | 90 | 0.030 |
Why?
| Staphylococcal Infections | 1 | 2019 | 267 | 0.030 |
Why?
| Image Interpretation, Computer-Assisted | 1 | 2016 | 105 | 0.030 |
Why?
| Logistic Models | 1 | 2018 | 900 | 0.030 |
Why?
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 140 | 0.030 |
Why?
| Melphalan | 1 | 2016 | 178 | 0.030 |
Why?
| Heart | 1 | 2017 | 341 | 0.030 |
Why?
| Kidney Diseases | 1 | 2017 | 213 | 0.030 |
Why?
| Algorithms | 1 | 2018 | 625 | 0.030 |
Why?
| Echocardiography | 1 | 2017 | 400 | 0.030 |
Why?
| Time Factors | 1 | 2021 | 2935 | 0.030 |
Why?
| Myocardium | 1 | 2017 | 445 | 0.030 |
Why?
| Disease Management | 1 | 2015 | 178 | 0.030 |
Why?
| Thalidomide | 1 | 2016 | 378 | 0.030 |
Why?
| Longitudinal Studies | 1 | 2016 | 735 | 0.030 |
Why?
| Risk Assessment | 1 | 2018 | 1270 | 0.030 |
Why?
| Dose-Response Relationship, Drug | 1 | 2016 | 1372 | 0.030 |
Why?
| Ifosfamide | 1 | 2011 | 11 | 0.020 |
Why?
| Dacarbazine | 1 | 2011 | 10 | 0.020 |
Why?
| Carboplatin | 1 | 2011 | 54 | 0.020 |
Why?
| Tomography, X-Ray Computed | 1 | 2017 | 1164 | 0.020 |
Why?
| Etoposide | 1 | 2011 | 77 | 0.020 |
Why?
| United States | 1 | 2022 | 4955 | 0.020 |
Why?
| Treatment Failure | 1 | 2011 | 118 | 0.020 |
Why?
| Fatal Outcome | 1 | 2011 | 197 | 0.020 |
Why?
| Drug Administration Schedule | 1 | 2011 | 370 | 0.020 |
Why?
| Magnetic Resonance Imaging | 1 | 2017 | 1548 | 0.020 |
Why?
|
|
Thanendrarajan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|